Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation
Authors:
- 1 February 2016
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 51 (6) , 850-852
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced MelanomaJAMA Oncology, 2015
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T CellsClinical Cancer Research, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersBlood, 2009
- Graft-versus-leukemia effects of transplantation and donor lymphocytesBlood, 2008